A Nerstedt1, A Johansson, C X Andersson, E Cansby, U Smith, M Mahlapuu. 1. The Lundberg Laboratory for Diabetes Research, Center of Excellence for Cardiovascular and Metabolic Research, Department of Molecular and Clinical Medicine/Diabetes, The Sahlgrenska Academy, University of Gothenburg, Blå stråket 5, SE-413 45, Göteborg, Sweden.
Abstract
AIM/HYPOTHESIS: The aim of the study was to examine the possible role of AMP-activated protein kinase (AMPK) in the regulation of the inflammatory response induced by cytokine action in human liver cells. METHODS: IL-6-stimulated expression of the genes for acute-phase response markers serum amyloid A (SAA1, SAA2) and haptoglobin (HP) in the human hepatocarcinoma cell line HepG2 were quantified after modulation of AMPK activity by pharmacological agonists (5-amino-4-imidazole-carboxamideriboside [AICAR], metformin) or by using small interfering (si) RNA transfection. The intracellular signalling pathway mediating the effect of AMPK on IL-6-stimulated acute-phase marker expression was characterised by assessing the phosphorylation levels of the candidate protein signal transducer and activator of transcription 3 (STAT3) in response to AMPK agonists. RESULTS: AICAR and metformin markedly blunt the IL-6-stimulated expression of SAA cluster genes as well as of haptoglobin in a dose-dependent manner. Moreover, the repression of AMPK activity by siRNA significantly reversed the inhibition of SAA expression by both AICAR and metformin, indicating that the effect of the agonists is dependent on AMPK. For the first time we show that AMPK appears to regulate IL-6 signalling by directly inhibiting the activation of the main downstream target of IL-6, STAT3. CONCLUSIONS/ INTERPRETATION: We provide evidence for a key function of AMPK in suppression of the acute-phase response caused by the action of IL-6 in liver, suggesting that AMPK may act as an intracellular link between chronic low-grade inflammation and metabolic regulation in peripheral metabolic tissues.
AIM/HYPOTHESIS: The aim of the study was to examine the possible role of AMP-activated protein kinase (AMPK) in the regulation of the inflammatory response induced by cytokine action in human liver cells. METHODS:IL-6-stimulated expression of the genes for acute-phase response markers serum amyloid A (SAA1, SAA2) and haptoglobin (HP) in the human hepatocarcinoma cell line HepG2 were quantified after modulation of AMPK activity by pharmacological agonists (5-amino-4-imidazole-carboxamideriboside [AICAR], metformin) or by using small interfering (si) RNA transfection. The intracellular signalling pathway mediating the effect of AMPK on IL-6-stimulated acute-phase marker expression was characterised by assessing the phosphorylation levels of the candidate protein signal transducer and activator of transcription 3 (STAT3) in response to AMPK agonists. RESULTS:AICAR and metformin markedly blunt the IL-6-stimulated expression of SAA cluster genes as well as of haptoglobin in a dose-dependent manner. Moreover, the repression of AMPK activity by siRNA significantly reversed the inhibition of SAA expression by both AICAR and metformin, indicating that the effect of the agonists is dependent on AMPK. For the first time we show that AMPK appears to regulate IL-6 signalling by directly inhibiting the activation of the main downstream target of IL-6, STAT3. CONCLUSIONS/ INTERPRETATION: We provide evidence for a key function of AMPK in suppression of the acute-phase response caused by the action of IL-6 in liver, suggesting that AMPK may act as an intracellular link between chronic low-grade inflammation and metabolic regulation in peripheral metabolic tissues.
Authors: Neil B Ruderman; Charlotte Keller; Ann-Marie Richard; Asish K Saha; Zhijun Luo; Xiaoqin Xiang; Mercedes Giralt; Vladimir B Ritov; Elizabeth V Menshikova; David E Kelley; Juan Hidalgo; Bente K Pedersen; Meghan Kelly Journal: Diabetes Date: 2006-12 Impact factor: 9.461
Authors: Adam Steensberg; Christian P Fischer; Massimo Sacchetti; Charlotte Keller; Takuya Osada; Peter Schjerling; Gerrit van Hall; Mark A Febbraio; Bente Klarlund Pedersen Journal: J Physiol Date: 2003-03-14 Impact factor: 5.182
Authors: T-B Kim; S Y Kim; K-A Moon; C-S Park; M K Jang; E S Yun; Y S Cho; H-B Moon; K-Y Lee Journal: Clin Exp Allergy Date: 2007-09-17 Impact factor: 5.018
Authors: S Franckhauser; I Elias; V Rotter Sopasakis; T Ferré; I Nagaev; C X Andersson; J Agudo; J Ruberte; F Bosch; U Smith Journal: Diabetologia Date: 2008-04-24 Impact factor: 10.122
Authors: Barbara Brunmair; Katrin Staniek; Florian Gras; Nicole Scharf; Aleksandra Althaym; Renate Clara; Michael Roden; Erich Gnaiger; Hans Nohl; Werner Waldhäusl; Clemens Fürnsinn Journal: Diabetes Date: 2004-04 Impact factor: 9.461
Authors: Y D Kim; Y H Kim; Y M Cho; D K Kim; S W Ahn; J M Lee; D Chanda; M Shong; C H Lee; H S Choi Journal: Diabetologia Date: 2012-02-21 Impact factor: 10.122
Authors: A Nerstedt; E Cansby; C X Andersson; M Laakso; A Stančáková; M Blüher; U Smith; M Mahlapuu Journal: Diabetologia Date: 2012-03-04 Impact factor: 10.122
Authors: R Krishnapuram; E J Dhurandhar; O Dubuisson; H Kirk-Ballard; S Bajpeyi; N Butte; M S Sothern; E Larsen-Meyer; S Chalew; B Bennett; A K Gupta; F L Greenway; W Johnson; M Brashear; G Reinhart; T Rankinen; C Bouchard; W T Cefalu; J Ye; R Javier; A Zuberi; N V Dhurandhar Journal: Am J Physiol Endocrinol Metab Date: 2011-01-25 Impact factor: 4.310
Authors: Brendan Gongol; Traci Marin; I-Chen Peng; Brian Woo; Marcy Martin; Stephanie King; Wei Sun; David A Johnson; Shu Chien; John Y-J Shyy Journal: Proc Natl Acad Sci U S A Date: 2013-02-04 Impact factor: 11.205
Authors: Finosh G Thankam; Matthew F Dilisio; Kaitlin A Dougherty; Nicholas E Dietz; Devendra K Agrawal Journal: Expert Rev Clin Immunol Date: 2016-06-13 Impact factor: 4.473